EVLO - Evelo Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.87
-0.29 (-3.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.16
Open8.17
Bid6.18 x 800
Ask9.25 x 2200
Day's Range7.87 - 8.36
52 Week Range4.90 - 15.89
Volume99,362
Avg. Volume62,398
Market Cap252.307M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
Trade prices are not sourced from all markets
  • GlobeNewswire

    Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild to moderate psoriasis and the potential for EDP1815 as a new therapeutic option for patients. As part of the event, Mark G. Lebwohl, M.D., Waldman Professor and Chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, will present an overview of the current treatment landscape and burden of disease in mild to moderate psoriasis. Additionally, Evelo management will review the recently announced positive interim clinical data from its ongoing Phase 1b clinical trial evaluating EDP1815 in mild to moderate psoriasis, and discuss its planned path forward in psoriasis and broader significance to the Company’s platform.

  • GlobeNewswire

    Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors

    Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. Mr. Epstein has been a director of Evelo since March 2017. Noubar Afeyan, Ph.D., a co-founder of Evelo and chief executive officer of Flagship Pioneering, is stepping down after serving as chairman of the Board since Evelo’s founding in 2014.

  • GlobeNewswire

    Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th at 10:35 am ET. A live audio webcast of the fireside chat will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects.

  • Evelo Biosciences, Inc. (EVLO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Evelo Biosciences, Inc. (EVLO) Q2 2019 Earnings Call Transcript

    EVLO earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced positive interim clinical data from the first cohort of patients with mild to moderate psoriasis from its ongoing Phase 1b trial of EDP1815, its clinical candidate for the treatment of inflammatory diseases. 12 patients with mild to moderate psoriasis were randomized 2:1 to receive daily, oral administration of 550mg (1x dose) of EDP1815, or placebo, for 28 days. Secondary and exploratory endpoints included lesion severity score (LSS), a measure of clinical activity, cellular histological biomarkers and blood immune cell biomarkers taken from biopsies and blood samples, respectively, at the start and end of the 28-day dosing period.

  • GlobeNewswire

    Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results

    -EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo--Clinical Response Observed Consistent with Reductions in Cellular Histological and.

  • GlobeNewswire

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Tuesday, August 6, 2019 to report its second quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures

    Evelo Biosciences, Inc. (EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures (K2HV), a healthcare investment firm. “We are pleased to announce this agreement, which increases our financial flexibility as we advance our clinical portfolio of oral biologics in inflammation and oncology,” said Jonathan Poole, chief financial officer of Evelo.

  • GlobeNewswire

    Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that Theo Melas-Kyriazi, Executive Partner at Flagship Pioneering, has been appointed to its Board of Directors. In addition, the Company announced that Noubar Afeyan, Ph.D., co-founder of Kaleido and CEO of Flagship Pioneering, is stepping down after serving as a Board member since Kaleido’s founding within Flagship Labs in 2015.

  • GlobeNewswire

    Evelo Biosciences to Present at Upcoming Investor Conferences in June

    CAMBRIDGE, Mass., May 30, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the.

  • Introducing Evelo Biosciences (NASDAQ:EVLO), The Stock That Slid 53% In The Last Year
    Simply Wall St.

    Introducing Evelo Biosciences (NASDAQ:EVLO), The Stock That Slid 53% In The Last Year

    The nature of investing is that you win some, and you lose some. And unfortunately for Evelo Biosciences, Inc...

  • GlobeNewswire

    Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body, today announced that management will present a corporate overview at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22nd at 8:30am ET. A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with striking therapeutic effects throughout the body.

  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript
    Motley Fool

    Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript

    EVLO earnings call for the period ending March 31, 2019.

  • GlobeNewswire

    Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights

    -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold:Plan to Introduce New Formulation into Ongoing Clinical Trials in Second.

  • GlobeNewswire

    Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, May 2, 2019 to report its first quarter financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”),  a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a corporate overview at the 18th Annual Needham Healthcare Conference on Wednesday, April 10th at 2:10pm ET. Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Evelo’s product candidates are single strains of microbes, selected for defined pharmacological properties.

  • GlobeNewswire

    Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference

    CAMBRIDGE, Mass., March 04, 2019 -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new.

  • GlobeNewswire

    Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma ---- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials.

  • GlobeNewswire

    Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, February 14, 2019 to report its fourth quarter and full year 2018 financial results and discuss recent business updates. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

  • GlobeNewswire

    Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer. This open-label clinical trial, led by Dr. Jason J. Luke, M.D., FACP, will evaluate the safety, tolerability, and efficacy of EDP1503 in combination with KEYTRUDA® in up to 70 patients with metastatic melanoma who are previously untreated or who have relapsed following treatment with an anti-PD-1 inhibitor.

  • GlobeNewswire

    Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

    Evelo Biosciences, Inc. (EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of cancer.

  • GlobeNewswire

    Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

    Evelo Biosciences, Inc. (EVLO) (“Evelo”),  a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced that management will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 2:00 p.m. ET. Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a new modality of medicines designed to act on the gut-body network. Evelo’s product candidates are orally-delivered, single strains of microbes, selected for defined pharmacological properties.

  • GlobeNewswire

    Evelo Enters into Clinical Trial Collaboration Agreement with Merck

    Evelo Biosciences, Inc. (EVLO) (“Evelo”), a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada). The collaboration will evaluate EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in multiple cancer indications.

  • GlobeNewswire

    Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis

    Evelo Biosciences, Inc. (EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced first dosing in its Phase 1b clinical trial of EDP1815 for the treatment of psoriasis and atopic dermatitis. EDP1815 is Evelo’s second monoclonal microbial product candidate being developed for the treatment of inflammatory diseases. "Psoriasis and atopic dermatitis patients are underserved by current medicines, particularly in the moderate patient populations, where the potential efficacy, tolerability and convenience benefits of monoclonal microbials could be profound," said Andrea Itano, Ph.D., head of immuno-inflammatory diseases at Evelo.